7/24/2023 0 Comments Keynote 775As we have also talked about, checkpoint inhibitors have shown strong efficacy in the treatment of MSI-high or mismatch repair-deficient endometrial cancers. With that, essentially, as we have all talked about already, there continues to be a huge unmet need for the development of effective therapies for advanced recurrent endometrial cancers, specifically for those that are microsatellite stable or mismatch repair proficient because they comprise the majority of the recurrent disease space. It has been a wonderful experience, so I will humbly present this on behalf of all my colleagues, but this has been a labor of love on all our parts. It has been a beautiful collaboration, not only among our United States colleagues but also our international colleagues we have all become great friends. I have to say, though, before I begin, that this really has been a labor of love. I will try to add some Indian masala to the presentation. It was just presented at the Society of Gynecologic Oncology annual meeting. Take your time and tell us about this trial. I am so excited for you to take quite a bit of time. The real finish line is bringing this to the clinic, and you are very close. The finish line will be publication in The New England Journal of Medicine, which is virtually assured. I know this has been a substantial portion of your career, and you are close to the finish line. If you are a patient with MSI-high tumors, you get pembrolizumab if you’re non–MSI-high, you get pembrolizumab and lenvatinib, but we needed a higher level of evidence. In the US, it’s been, “Oh, all second-line patients basically need pembrolizumab,” since September of last year. Certainly, the accelerated approval came in September of 2020 in the non–MSI-high subgroup. It was the physicians’ choice of chemotherapy, and we are going to hear what those medications were, versus pembrolizumab and lenvatinib in all-comers. This is a randomized phase 3 trial in second-line endometrial cancer. It is a collaborative study between 2 sponsors. This trial has 2 names many people call it KEYNOTE-775. Vicky, I was excited to hear you because you have been very busy with this trial. Brad Monk, MD, FACOG, FACS: I was so excited when all of you agreed to participate.
0 Comments
Leave a Reply. |